Clinical Guidelines Updated for Evaluation, Management, Treatment of CKD
WEDNESDAY, March 19, 2025 -- In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a synopsis of which was published online March 11 in the Annals of Internal Medicine, updated recommendations are presented for the evaluation, management, and treatment of chronic kidney disease (CKD).
In the synopsis, Magdalena Madero, M.D., from the Instituto Nacional de Cardiología Ignacio Chávez in Mexico City, and colleagues summarize the updated recommendations for the evaluation, management, and treatment of CKD in children and adults who are not receiving kidney replacement therapy. The authors note that the evidence was reviewed by an independent Evidence Review Team, and its certainty was graded.
The full guideline included 28 recommendations for which there is the greatest evidence and 141 practice points, which reflect the expert opinion of the group. Recommendations include more emphasis on the use of cystatin C for assessment of glomerular filtration rate; use of point-of-care testing in remote areas where laboratory access may be limited; use of an individualized risk-based approach for prediction of kidney failure; sodium-glucose cotransporter 2 inhibitors for CKD patients with and without diabetes; and use of statins for adults older than 50 years and for those with CKD.
"The KDIGO 2024 guideline navigates clinicians through the identification, improved evaluation, and targeted treatment and management of persons with CKD," the authors write. "Evaluation of CKD emphasizes the role of cystatin C for better accuracy of GFR, especially in clinical situations where creatinine falls short."
KDIGO 2024 Clinical Practice Guideline
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Guidance Issued on Impact, Management of Potassium, Phosphorus in CKD
THURSDAY, Sept. 25, 2025 -- Guidance is presented for understanding the impact of potassium and phosphorus additives on people with chronic kidney disease (CKD) and managing their...
Machine, Deep Learning Models Improve Prediction of CKD Progression
MONDAY, Sept. 15, 2025 -- Machine learning and deep learning models applied to integrated clinical and claims data can improve prediction of chronic kidney disease (CKD)...
Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
MONDAY, Sept. 8, 2025 -- The addition of baxdrostat, an aldosterone synthase inhibitor, to background therapy yields a significant reduction in seated systolic blood pressure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.